ClinicalTrials.gg
Drug

Orelabrutinib clinical trials

Also written ICP-022.

studies test it
94
open now
64
in phase 3
14
first study started
2017

How each study uses orelabrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the orelabrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Orelabrutinib
56
Induction phase
3
Orelabrutinib Tablets
2

Development codes

ICP-022
14

Studies by the year they started

94 studies that test it; most in 2026 (16)

Studies that test orelabrutinib, by start year
YearStudies
20171
20182
20195
20203
202114
202212
202312
202414
202515
202616

Who runs them

Industry 26 · Other 68

Beijing InnoCare Pharma Tech Co., Ltd. (22) · Ruijin Hospital (11) · The First Affiliated Hospital with Nanjing Medical University (7) · Peking Union Medical College Hospital (5) · Sun Yat-sen University (4) · The First Affiliated Hospital of Soochow University (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (4) · Institute of Hematology & Blood Diseases Hospital, China (3)

Often tested with

Tested in the same studies.

R-CHOP Regimen (4) · Lenalidomide (3) · Pola-R-CHP Regimen (3) · Zuberitamab (2) · Rituximab (2) · Polatuzumab vedotin (2) · Venetoclax (2) · Obinutuzumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Orelabrutinib is the comparator. A study of two new drugs counts under both.

  • 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 13, 2 in phase 3

Studies that test orelabrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses orelabrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 94

See all 94 studies that test orelabrutinib →

Given beside what is tested · 4 — orelabrutinib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with orelabrutinib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call orelabrutinib · ClinicalTrials.gg INT002046

  • MeSH (NLM) C000729508orelabrutinibOne source ClinicalTrials.gov
  • UNII (FDA) WJA5UO9E10ORELABRUTINIBConfirmed FDA, Wikidata
  • Wikidata Q126122244orelabrutinibConfirmed FDA, Wikidata
  • NCI Thesaurus C156173OrelabrutinibOne source FDA
  • DrugBank DB16272One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.